A d-peptide-based oral nanotherapeutic modulates the PD-1/PD-L1 interaction for tumor immunotherapy
BackgroundPD-1/PD-L1 immune checkpoint inhibitors are currently the most commonly utilized agents in clinical practice, which elicit an immunostimulatory response to combat malignancies. However, all these inhibitors are currently administered via injection using antibody-based therapies, while ther...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2023-07-01
|
| Col·lecció: | Frontiers in Immunology |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1228581/full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|